WO2003084591A1 - Dispositifs nasaux - Google Patents
Dispositifs nasaux Download PDFInfo
- Publication number
- WO2003084591A1 WO2003084591A1 PCT/IB2003/001785 IB0301785W WO03084591A1 WO 2003084591 A1 WO2003084591 A1 WO 2003084591A1 IB 0301785 W IB0301785 W IB 0301785W WO 03084591 A1 WO03084591 A1 WO 03084591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flow
- delivery device
- gas
- subject
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
- A61M15/0098—Activated by exhalation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0666—Nasal cannulas or tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
Definitions
- the present invention relates to a nasal delivery device for and a method of delivering substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.
- the nasal airway 1 comprises the two nasal cavities 2, 3 separated by the nasal septum 4, which airway 1 includes numerous ostia, such as the paranasal sinus ostia 5 connected to the paranasal sinuses 6 and the tubal ostia 7 connected to the tuba auditiva 8 and the middle ears 9, and olfactory cells, and is lined by the nasal mucosa.
- the nasal airway 1 can communicate with the nasopharynx, the oral cavity and the lower airway, with the nasal airway 1 being in selective communication with the anterior region of the nasopharynx and the oral cavity by opening and closing of the oropharyngeal velum.
- nasal inflammation specifically rhinitis
- allergic and non-allergic inflammation of the nasal airway can typically effect between 10 and 20 % of the population, with nasal congestion of the erectile tissues of the nasal concha, lacrimation, secretion of watery mucus, sneezing and itching being the most common symptoms.
- nasal congestion impedes nasal breathing and promotes oral breathing, leading to snoring and sleep disturbance.
- Other nasal conditions include nasal polyps which arise from the paranasal sinuses, hypertrophic adenoids, secretory otitis media, sinus disease and reduced olfaction.
- the topical administration of medicaments is preferable, particularly where the nasal mucosa is the prime pathological pathway, such as in treating or relieving nasal congestion.
- Medicaments that are commonly topically delivered include decongestants, anti-histamines, cromoglycates, steroids and antibiotics.
- topical steroids have been shown to have an effect on nasal congestion.
- Topical decongestants have also been suggested for use in relieving nasal congestion.
- the treatment of hypertrophic adenoids and chronic secretory otitis media using topical decongestants, steroids and anti-microbial agents, although somewhat controversial, has also been proposed.
- the topical administration of pharmaceuticals has been used to treat or at least relieve symptoms of inflammation in the anterior region of the nasopharynx, the paranasal sinuses and the auditory tubes.
- Medicaments can also be systemically delivered through the nasal pathway, the nasal pathway offering a good administration route for the systemic delivery of pharmaceuticals, such as hormones, for example, oxytocin and calcitionin, and analgetics, such as anti-migraine compositions, as the high blood flow and large surface area of the nasal mucosa advantageously provides for rapid systemic uptake.
- pharmaceuticals such as hormones, for example, oxytocin and calcitionin, and analgetics, such as anti-migraine compositions
- Nasal delivery is also expected to be advantageous for the administration of medicaments requiring a rapid onset of action, for example, analgetics, anti-emetics, insulin, anti-epileptics, sedatives and hypnotica, and also other pharmaceuticals, for example, cardio-vascular drugs. It is envisaged that nasal administration will provide for a fast onset of action, at a rate similar to that of injection and at a rate much faster than that of oral administration. Indeed, for the treatment of many acute conditions, nasal administration is advantageous over oral administration, since gastric stasis can further slow the onset of action following oral administration.
- nasal delivery could provide an effective delivery route for the administration of proteins and peptides as produced by modern biotechnological techniques.
- the metabolism in the intestines and the first-pass- effect in the liver represent significant obstacles for reliable and cost-efficient delivery.
- nasal delivery using the nasal delivery technique of the present invention will prove effective in the treatment of many common neurological diseases, such as Alzheimer's, Parkinson's, psychiatric diseases and intracerebral infections, where not possible using existing techniques.
- the nasal delivery technique of the present invention allows for delivery to the olfactory region, which region is located in the superior region of the nasal cavities and represents the only region where it is possible to circumvent the blood-to-brain barrier (BBB) and enable communication with the cerebrospinal fluid (CSF) and the brain.
- BBB blood-to-brain barrier
- CSF cerebrospinal fluid
- nasal delivery technique of the present invention will allow for the effective delivery of vaccines.
- liquids in particular saline solutions
- saline solutions are commonly practised to remove particles and secretions, as well as to improve the mucociliary activity of the nasal mucosa.
- WO-A-00/51672 discloses a delivery device for delivering substance, in particular a medicament, in a bi-directional flow through the nasal cavities, that is, an air flow which passes into one nostril, around the posterior margin of the nasal septum and in the opposite direction out of the other nostril.
- This bi-directional air flow advantageously acts to stimulate the sensory nerves in the nasal mucosa, thereby conditioning the subject for the delivery and providing a more comfortable delivery situation.
- Such delivery units include aerosol canisters as used in pressurized metered dose inhalers (pMDIs) and mechanical delivery pumps, such as liquid spray pumps.
- pMDIs pressurized metered dose inhalers
- liquid spray pumps such as liquid spray pumps
- Spacers In the field of inhalation technology, spacers have been developed as a means of overcoming this particular problem. Spacers are essentially chambers into which an aerosol spray of substance is delivered and from which the substance is inhaled, typically by a subject inhaling from an outlet port. One such spacer is disclosed in WO- A-92/04065.
- the present invention provides a nasal delivery device for delivering substance to a nasal airway of a subject, comprising: a nosepiece for fitting to a nostril of a subject; a chamber fluidly connected to the nosepiece and including a flow regulator for generating a regulated gas stream within the chamber along a flow axis in a flow direction towards the nosepiece; and a delivery unit comprising a substance supply unit and a plurality of nozzles fluidly connected to the substance supply unit each for delivering an aerosol spray into the gas stream.
- the nozzles of the delivery unit are each configured to deliver an aerosol spray towards the flow axis in a direction inclined to the flow axis and opposing the flow direction.
- the nozzles of the delivery unit are each configured to deliver an aerosol spray towards the flow axis in a direction substantially orthogonal to the flow direction. In a further embodiment the nozzles of the delivery unit are each configured to deliver an aerosol spray towards the flow axis in a direction inclined to the flow axis and in the flow direction.
- the nozzles of the delivery unit are radially disposed about the flow axis.
- pairs of the nozzles are diametrically opposed.
- the flow regulator is configured to focus and accelerate a gas flow provided thereto and generate a regulated gas stream of increased velocity within the chamber along the flow axis.
- the flow regulator comprises a flow passage including a focusing section of decreasing radial dimension in the flow direction, which focusing section acts to focus and accelerate a gas flow supplied thereto.
- the flow passage includes a delivery section of substantially uniform radial dimension downstream of the focusing section.
- the delivery device further comprises: a mouthpiece through which the subject in use exhales.
- the delivery device further comprises: a gas supply channel for supplying a gas flow to the flow regulator.
- the mouthpiece is fluidly connected to the gas supply channel, whereby the gas flow is an air flow developed by an exhalation breath of the subject.
- the delivery device further comprises: a gas supply unit which is fluidly connected to the gas supply channel for delivering a gas flow through the gas supply channel.
- a gas supply unit which is fluidly connected to the gas supply channel for delivering a gas flow through the gas supply channel.
- the mouthpiece is fluidly connected to the gas supply unit and the gas supply unit is an exhalation breath actuatable unit which is actuated on exhalation by the subject.
- the substance supply unit comprises an aerosol canister.
- the substance supply unit comprises a delivery pump.
- the delivery pump comprises a liquid spray pump.
- the present invention provides a nasal delivery device for delivering substance to a nasal airway of a subject, comprising: a nosepiece for fitting to a nostril of a subject; a chamber fluidly connected to the nosepiece and including a flow regulator for generating a regulated gas stream within the chamber along a flow axis in a flow direction towards the nosepiece, wherein the flow regulator is configured to focus and accelerate a gas flow provided thereto and generate a regulated gas stream of increased velocity within the chamber along the flow axis; and a delivery unit comprising a substance supply unit and at least one nozzle fluidly connected to the substance supply unit for delivering at least one aerosol spray into the gas stream.
- the at least one nozzle of the delivery unit is configured to deliver at least one aerosol spray substantially along the flow axis in a direction opposing the flow direction.
- the at least one nozzle of the delivery unit is configured to deliver at least one aerosol spray towards the flow axis in a direction inclined to the flow axis and opposing the flow direction.
- the at least one nozzle of the delivery unit is configured to deliver at least one aerosol spray towards the flow axis in a direction substantially orthogonal to the flow direction. In a yet further embodiment the at least one nozzle of the delivery unit is configured to deliver at least one aerosol spray towards the flow axis in a direction inclined to the flow axis and in the flow direction.
- the delivery unit comprises a plurality of nozzles.
- the nozzles of the delivery unit are radially disposed about the flow axis.
- pairs of the nozzles are diametrically opposed.
- the flow regulator comprises a flow passage including a focusing section of decreasing radial dimension in the flow direction, which focusing section acts to focus and accelerate a gas flow supplied thereto.
- the flow passage includes a delivery section of substantially uniform radial dimension disposed downstream of the focusing section.
- the delivery device further comprises: a mouthpiece through which the subject in use exhales.
- the delivery device further comprises: a gas supply channel for supplying a gas flow to the flow regulator.
- the mouthpiece is fluidly connected to the gas supply channel, whereby the gas flow is an air flow developed by an exhalation breath of the subject.
- the delivery device further comprises: a gas supply unit which is fluidly connected to the gas supply channel for delivering a gas flow through the gas supply channel.
- the mouthpiece is fluidly connected to the gas supply unit and the gas supply unit is an exhalation breath actuatable unit which is actuated on exhalation by the subject.
- the substance supply unit comprises an aerosol canister.
- the substance supply unit comprises a delivery pump.
- the delivery pump comprises a liquid spray pump.
- the present invention provides a nasal delivery device for delivering substance to a nasal airway of a subject, comprising: a nosepiece for fitting to a nostril of a subject; a chamber fluidly connected to the nosepiece and including a flow regulator for generating a regulated gas stream in a flow direction within the chamber; and a delivery unit comprising a substance supply unit and at least one nozzle fluidly connected to the substance supply unit for delivering at least one aerosol spray into the gas stream.
- the present invention provides a method of delivering substance to a nasal airway of a subject, comprising the steps of: fitting a nosepiece to a nostril of a subject; providing a gas flow; generating from the gas flow a regulated gas stream within a chamber along a flow axis in a flow direction towards the nosepiece; and delivering a plurality of aerosol sprays into the gas stream.
- the aerosol sprays are delivered towards the flow axis in a direction inclined to the flow axis and opposing the flow direction.
- the aerosol sprays are delivered towards the flow axis in a direction substantially orthogonal to the flow direction.
- the aerosol sprays are delivered towards the flow axis in a direction inclined to the flow axis and in the flow direction.
- the aerosol sprays are delivered radially towards the flow axis.
- pairs of the aerosol sprays are directed oppositely towards the flow axis.
- the step of generating a regulated gas stream comprises the step of: focusing and accelerating the gas flow to generate a regulated gas stream of increased velocity within the chamber along the flow axis.
- the method further comprises the step of: the subject exhaling through a mouthpiece.
- the gas flow is an air flow developed by an exhalation breath of the subject.
- gas flow is a gas flow separate to an exhalation breath of the subject.
- the aerosol sprays are generated by an aerosol canister.
- the aerosol sprays are generated by a spray pump, either as a liquid or powder aerosol spray.
- the present invention provides a method of delivering substance to a nasal airway of a subject, comprising the steps of: fitting a nosepiece to a nostril of a subject; providing a gas flow; focusing and accelerating the gas flow to generate a gas stream of increased velocity within a chamber along a flow axis in a flow direction towards the nosepiece; and delivering at least one aerosol spray into the gas stream.
- the at least one aerosol spray is delivered substantially along the flow axis in a direction opposing the flow direction.
- the at least one aerosol spray is delivered towards the flow axis in a direction inclined to the flow axis and opposing the flow direction.
- the at least one aerosol spray is delivered towards the flow axis in a direction substantially orthogonal to the flow direction. In a yet further embodiment the at least one aerosol spray is delivered towards the flow axis in a direction inclined to the flow axis and in the flow direction.
- the step of delivering at least one aerosol spray into the gas stream comprises the step of: delivering a plurality of aerosol sprays into the gas stream.
- the aerosol sprays are delivered radially towards the flow axis.
- pairs of the aerosol sprays are directed oppositely towards the flow axis.
- the method further comprises the step of: the subject exhaling through a mouthpiece.
- the gas flow is an air flow developed by an exhalation breath of the subject.
- gas flow is a gas flow separate to an exhalation breath of the subject.
- the at least one aerosol spray is generated by an aerosol canister.
- the at least one aerosol spray is generated by a spray pump, either as a liquid or powder aerosol spray.
- Figure 1 schematically illustrates the nasal airway of a human subject
- Figure 2(a) schematically illustrates a nasal delivery device in accordance with a first embodiment of the present invention
- Figure 2(b) illustrates a part-sectional view (along section I-I in Figure 2(a)) of the nasal delivery device of Figure 2(a);
- Figure 2(c) illustrates the nasal delivery device of Figure 2(a) in the actuated configuration
- Figure 3(a) schematically illustrates a nasal delivery device in accordance with a second embodiment of the present invention
- Figure 3(b) illustrates a part-sectional view (along section II-II in Figure 3(a)) of the nasal delivery device of Figure 3(a);
- Figure 3(c) illustrates the nasal delivery device of Figure 3(a) in the actuated configuration
- Figure 4(a) schematically illustrates a nasal delivery device in accordance with a third embodiment of the present invention
- Figure 4(b) illustrates a part-sectional view (along section III-III in Figure 4(a)) of the nasal delivery device of Figure 4(a);
- Figure 4(c) illustrates the nasal delivery device of Figure 4(a) in the actuated configuration.
- Figures 2(a) to (c) illustrate a nasal delivery device in accordance with a first embodiment of the present invention.
- the delivery device comprises a chamber 13, in this embodiment a tubular member, through which a gas flow, in this embodiment an air flow developed by the exhalation breath of a subject, is delivered, a nosepiece 15 for fitting to a nostril of the subject which is in fluid communication with one, the downstream, end of the chamber 13, a gas supply channel 16, one end of which is in fluid communication with the other, upstream, end of the chamber 13, and a mouthpiece 17 through which the subject exhales and which is in fluid communication with the other end of the gas supply channel 16.
- a gas flow in this embodiment an air flow developed by the exhalation breath of a subject
- the chamber 13 includes a flow regulator 19 which is disposed at the other, upstream, end thereof and acts to provide a focused, high-velocity gas stream within the chamber 13 along the longitudinal axis thereof, this being the flow axis of the gas stream.
- the flow regulator 19 includes a single flow passage 21 which is centered on the longitudinal axis of the chamber 13, and acts to focus and accelerate a gas flow delivered through the gas supply channel 16 and generate a focused, high- velocity gas stream downstream thereof, where the gas stream has a smaller radial dimension than the chamber 13.
- the flow passage 21 includes a first, focusing section 21a which is of reducing radial dimension in a downstream direction, in this embodiment of frusto- conical section, and acts to focus and accelerate a gas flow delivered through the gas supply channel 16, and a second, delivery section 21b, in this embodiment of cylindrical section, which is disposed downstream of the focusing section 21a and acts to direct the gas stream.
- the gas stream exiting the flow regulator 19 is substantially turbulent.
- the flow regulator 19 could be configured to provide a substantially laminar flow, for example, by extending the length of the delivery section 21b of the flow passage 21.
- the delivery device further comprises a delivery unit 23 for delivering an aerosol spray of substance into the chamber 13.
- the delivery unit 23 comprises a nozzle unit 25 which includes a nozzle 27 for delivering an aerosol spray of substance, and a substance supply unit 29 for delivering a metered dose of substance to the nozzle unit 25.
- the nozzle 27 of the nozzle unit 25 faces in a direction upstream of the nosepiece 15, that is, in a direction opposing the gas flow through the chamber 13, and is disposed so as to be co-axial with the flow axis, that is, the longitudinal axis of the flow passage 21 of the flow regulator 19, whereby an aerosol spray, when delivered from the nozzle 27, is acted upon by the high-velocity gas stream exiting the flow regulator 19 such as to rapidly decelerate the particles of the aerosol spray, which particles, once decelerated, are then entrained by the gas flow through the chamber 13.
- the nozzle 27 of the nozzle unit 25 could face in other directions, typically orthogonally to the flow axis or in the direction of the nosepiece 15.
- the substance supply unit 29 is an aerosol canister for delivering a metered volume of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing a medicament, either as a suspension or solution.
- a propellant preferably a hydrofluoroalkane (HFA) propellant or the like
- the substance supply unit 29 is primeable, in this embodiment by loading a biasing element, and includes a release mechanism, which, when triggered, releases the biasing element and actuates the substance supply unit 29 to deliver a metered dose of substance.
- the substance supply unit 29 could comprise a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of substance on actuation thereof.
- the nosepiece 15 is fitted to a nostril of a subject and the mouthpiece 17 is gripped in the lips of the subject.
- the subject then begins to exhale through the mouthpiece 17, which exhalation acts to close the oropharyngeal velum of the subject and deliver a gas flow through the gas supply channel 16, the chamber 13 and the nasal airway 1 of the subject, which gas flow is focused and accelerated by the flow regulator 19 at the upstream end of the chamber 13 to provide a focussed, high-velocity gas stream.
- the subject then actuates the substance supply unit 29 to deliver a metered dose of substance through the nozzle 27 of the nozzle unit 25, which nozzle 27 generates an aerosol spray in a direction opposing the direction of the high-velocity gas stream from the flow regulator 19.
- the aerosol spray when delivered from the nozzle 27, is acted upon by the high-velocity gas stream exiting the flow regulator 19 such as to rapidly decelerate the particles of the aerosol spray, which particles, once decelerated, are then entrained by the gas flow through the chamber 13.
- the particles of the generated aerosol as delivered to the nasal airway 1 have the same velocity as the entraining gas flow, and thus deposition on unwanted surfaces, which would result where the particles are delivered directly to the nosepiece 15, is avoided.
- Figures 3(a) to (c) illustrate a nasal delivery device in accordance with a second embodiment of the present invention.
- the delivery device of this embodiment is very similar to the delivery device of the above-described first embodiment, and thus, in order to avoid unnecessary duplication of description, only the differences will be described in detail, with like reference signs designating like parts
- the delivery device of this embodiment differs from that of the above-described first embodiment in further comprising an exhalation breath actuatable gas supply unit 31 for delivering a gas flow through the gas supply channel 16 to the chamber 13 in response to exhalation by a subject, and in that the mouthpiece 17 is in fluid communication with the gas supply unit 31 and not the chamber 13, whereby a gas flow is delivered to the chamber 13, and hence the nasal airway 1, by the gas supply unit 31 in response to exhalation through the mouthpiece 17.
- Operation of the delivery device is the same as for the above-described first embodiment, with a gas flow being delivered to the chamber 13, and hence the nasal airway 1, by the gas supply unit 31 in response to exhalation through the mouthpiece 17, with the gas flow being delivered to the chamber 13 as a high- velocity gas stream.
- FIGS 4(a) to (c) illustrate a nasal delivery device in accordance with a third embodiment of the present invention.
- the delivery device comprises a chamber 43, in this embodiment a tubular member, through which a gas flow, in this embodiment an air flow developed by the exhalation breath of a subject, is delivered, a nosepiece 45 for fitting to a nostril of the subject which is in fluid communication with one, the downstream, end of the chamber 43, a gas supply channel 46, one end of which is in fluid communication with the other, upstream, end of the chamber 43, and a mouthpiece 47 through which the subject exhales and which is in fluid communication with the other end of the gas supply channel 46.
- the chamber 43 includes a flow regulator 49 which is disposed at the other, upstream, end thereof and acts to provide a focused, high-velocity gas stream within the chamber 43 along the longitudinal axis thereof, this being the flow axis of the gas stream.
- the flow regulator 49 includes a single flow passage 51 which is centered on the longitudinal axis of the chamber 43, and acts to focus and accelerate a gas flow delivered through the gas supply channel 46 and generate a focused, high-velocity gas stream downstream thereof, where the gas stream has a smaller radial dimension than the chamber 13.
- the flow passage 51 includes a first, focusing section 51a which is of reducing radial dimension in a downstream direction, in this embodiment of frusto- concave section, and acts to focus and accelerate a gas flow delivered through the gas supply channel 46, and a second, delivery section 51b, in this embodiment of cylindrical section, which is disposed downstream of the focusing section 51 a and acts to direct the gas stream.
- the gas stream exiting the flow regulator 49 is substantially turbulent.
- the flow regulator 49 could be configured to provide a substantially laminar flow, for example, by extending the length of the delivery section 51b of the flow passage 51.
- the delivery device further comprises a delivery unit 53 for delivering aerosol sprays of substance into the chamber 43.
- the delivery unit 53 comprises a nozzle unit 55 which includes a plurality of nozzles 57, in this embodiment four nozzles 57 disposed about the periphery of the chamber 43, for delivering aerosol sprays of substance, and a substance supply unit 59 for delivering a metered dose of substance to the nozzle unit 55.
- the nozzles 57 of the nozzle unit 55 are equi-angularly spaced, that is, at 90 degree intervals, and face inwardly in a direction substantially orthogonal to the flow direction of the gas stream, whereby aerosol sprays, when delivered from the nozzles 57, are acted upon by the high-velocity gas stream exiting the flow regulator 49 such as to be deflected in the flow direction of the gas flow through the chamber 43.
- the particles of the aerosol spray the particles are rapidly decelerated and entrained by the gas flow through the chamber 43.
- the aerosol sprays delivered by those nozzles 57 impinge on one another and cause deceleration of the particles of the aerosol sprays.
- the nozzles 57 of the nozzle unit 55 could be inclined relative to the flow axis of the gas stream such as to be directed in an upstream or downstream direction.
- the substance supply unit 59 is an aerosol canister for delivering a metered volume of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing a medicament, either as a suspension or solution.
- a propellant preferably a hydrofluoroalkane (HFA) propellant or the like
- the substance supply unit 59 is primeable, in this embodiment by loading a biasing element, and includes a release mechanism, which, when triggered, releases the biasing element and actuates the substance supply unit 59 to deliver a metered dose of substance.
- the substance supply unit 59 could comprise a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of substance on actuation thereof.
- the nosepiece 45 is fitted to a nostril of a subject and the mouthpiece 47 is gripped in the lips of the subject.
- the subject then begins to exhale through the mouthpiece 47, which exhalation acts to close the oropharyngeal velum of the subject and deliver a gas flow through the gas supply channel 46, the chamber 43 and the nasal airway 1 of the subject, which gas flow is focused and accelerated by the flow regulator 49 at the upstream end of the chamber 43 to provide a focussed, high-velocity gas stream.
- the subject then actuates the substance supply unit 59 to deliver a metered dose of substance through the nozzles 57 of the nozzle unit 55, which nozzles 57 generate aerosol sprays in a direction substantially orthogonal to the high-velocity gas stream developed in the chamber 43 by the flow regulator 49.
- the aerosol sprays when delivered from the nozzles 57, are acted upon by the high-velocity gas stream developed by the flow regulator 49 such as to be deflected in the flow direction through the chamber 43.
- the deflected particles of the aerosol sprays are rapidly decelerated and entrained by the gas flow through the chamber 43.
- the particles of the generated aerosol as delivered to the nasal airway 1 have the same velocity as the entraining gas flow, and thus deposition on unwanted surfaces, which would result where the particles are delivered directly to the nosepiece 45, is avoided.
- the nasal delivery device of the above-described third embodiment could be modified in the manner of the above-described second embodiment, that is, to include an exhalation breath actuatable gas supply unit 31 for delivering a gas flow through the chamber 43 which is separate to the exhalation breath of a subject.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Otolaryngology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003222401A AU2003222401A1 (en) | 2002-04-04 | 2003-04-04 | Nasal devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207817.8 | 2002-04-04 | ||
GB0207817A GB0207817D0 (en) | 2002-04-04 | 2002-04-04 | Nasal devices |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003084591A1 true WO2003084591A1 (fr) | 2003-10-16 |
Family
ID=9934265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/001785 WO2003084591A1 (fr) | 2002-04-04 | 2003-04-04 | Dispositifs nasaux |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003222401A1 (fr) |
GB (2) | GB0207817D0 (fr) |
WO (1) | WO2003084591A1 (fr) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006100102A1 (fr) * | 2005-03-24 | 2006-09-28 | Iph Establishment | Appareil pour l'administration de produits pharmaceutiques sous forme d'aérosol |
EP1754510A1 (fr) | 2005-08-19 | 2007-02-21 | Brainsgate Ltd. | Stimulation pour le traitement d'événements cérébraux et d'autres conditions |
WO2008091588A1 (fr) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Administration intranasale, buccale ou sublinguale d'analogues de métanicotine |
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
GB2424587B (en) * | 2005-02-23 | 2010-05-19 | Optinose As | Powder delivery devices |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
US20110023869A1 (en) * | 2006-11-28 | 2011-02-03 | Optinose As | Delivery devices |
US7908000B2 (en) | 2004-02-20 | 2011-03-15 | Brainsgate Ltd. | Transmucosal electrical stimulation |
ITBO20090755A1 (it) * | 2009-11-19 | 2011-05-20 | Giorgio Mezzoli | Dispositivo atto a somministrare per via nasale e/o buccale le soluzioni sotto forma di aerosol, doccia micronizzata o nebulizzazione. |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
USD759805S1 (en) | 2013-05-23 | 2016-06-21 | Optinose As | Nosepiece unit |
US9452272B2 (en) | 2003-08-14 | 2016-09-27 | Optinose As | Delivery devices |
US9522243B2 (en) | 2002-07-02 | 2016-12-20 | Optinose As | Nasal devices |
US9566402B2 (en) | 2003-05-20 | 2017-02-14 | Optinose As | Delivery Device and Method |
US9649456B2 (en) | 2007-04-05 | 2017-05-16 | Optinose As | Nasal administration |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
US10076615B2 (en) | 2007-04-05 | 2018-09-18 | Optinose As | Nasal delivery |
US10076614B2 (en) | 2012-02-24 | 2018-09-18 | Optinose As | Nasal delivery devices |
US10112021B2 (en) | 2006-06-08 | 2018-10-30 | Optinose As | Intranasal administration |
US10124132B2 (en) | 2006-03-06 | 2018-11-13 | Optinose As | Nasal delivery |
US10179216B2 (en) | 2012-02-24 | 2019-01-15 | Optinose As | Nasal delivery devices |
US10252010B2 (en) | 2007-10-03 | 2019-04-09 | Optinose As | Nasal delivery devices |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US10300229B2 (en) | 2012-02-24 | 2019-05-28 | Optinose As | Nasal delivery devices |
US10398859B2 (en) | 2004-09-15 | 2019-09-03 | Optinose As | Nasal delivery devices |
US10478574B2 (en) | 2006-01-19 | 2019-11-19 | Optinose As | Nasal administration |
US10525218B2 (en) | 2006-11-28 | 2020-01-07 | Optinose As | Nasal delivery devices |
US10639437B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
US10737045B2 (en) | 2003-08-28 | 2020-08-11 | Optinose As | Delivery devices |
US10765829B2 (en) | 2006-07-25 | 2020-09-08 | Optinose As | Delivery of gases to the nasal airway |
US10864334B2 (en) | 2006-03-23 | 2020-12-15 | Optinose As | Nasal delivery |
US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
JP2021509341A (ja) * | 2018-01-23 | 2021-03-25 | エスエイチエル・メディカル・アーゲー | エアロゾル発生器 |
US11291626B2 (en) | 2010-09-14 | 2022-04-05 | Optinose As | Nasal delivery of oxytocin |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
WO2023135237A1 (fr) | 2022-01-14 | 2023-07-20 | Cybin Irl Limited | Compositions de tryptamine et procédés |
WO2023156450A1 (fr) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Compositions de phénéthylamine thérapeutique et procédés d'utilisation |
WO2023156453A1 (fr) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Dérivés de phénétylamine, compositions et procédés d'utilisation |
WO2023186963A1 (fr) | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Combinaison d'oxyde nitreux et d'agonistes du récepteur 5-ht2a |
US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0602980D0 (en) * | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2470297A (en) * | 1947-09-04 | 1949-05-17 | Abbott Lab | Inhalator |
US5007419A (en) * | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
WO1992004065A1 (fr) | 1990-09-11 | 1992-03-19 | Walstrom Dennis R | Dispositif d'amenee pour medicaments atomises |
CA2207219A1 (fr) * | 1997-06-19 | 1998-12-19 | Leszek Marion Mankowski | Spacer et mode d'emploi |
WO2000051672A1 (fr) | 1999-03-03 | 2000-09-08 | Optinose As | Dispositif d'administration nasale |
US6302101B1 (en) * | 1999-12-14 | 2001-10-16 | Daniel Py | System and method for application of medicament into the nasal passage |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3923043A (en) * | 1973-09-28 | 1975-12-02 | Roman L Yanda | Method for acquisition of exhalation tidal volume and minute ventilation data |
US3971377A (en) * | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US4739754A (en) * | 1986-05-06 | 1988-04-26 | Shaner William T | Suction resistant inhalator |
US4790305A (en) * | 1986-06-23 | 1988-12-13 | The Johns Hopkins University | Medication delivery system |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
US6390090B1 (en) * | 1998-12-31 | 2002-05-21 | Samuel David Piper | Inhalation therapy apparatus |
-
2002
- 2002-04-04 GB GB0207817A patent/GB0207817D0/en not_active Ceased
-
2003
- 2003-04-04 AU AU2003222401A patent/AU2003222401A1/en not_active Abandoned
- 2003-04-04 GB GB0307820A patent/GB2389315B/en not_active Expired - Fee Related
- 2003-04-04 WO PCT/IB2003/001785 patent/WO2003084591A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2470297A (en) * | 1947-09-04 | 1949-05-17 | Abbott Lab | Inhalator |
US5007419A (en) * | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
WO1992004065A1 (fr) | 1990-09-11 | 1992-03-19 | Walstrom Dennis R | Dispositif d'amenee pour medicaments atomises |
CA2207219A1 (fr) * | 1997-06-19 | 1998-12-19 | Leszek Marion Mankowski | Spacer et mode d'emploi |
WO2000051672A1 (fr) | 1999-03-03 | 2000-09-08 | Optinose As | Dispositif d'administration nasale |
US6302101B1 (en) * | 1999-12-14 | 2001-10-16 | Daniel Py | System and method for application of medicament into the nasal passage |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
US9522243B2 (en) | 2002-07-02 | 2016-12-20 | Optinose As | Nasal devices |
US10286164B2 (en) | 2003-05-20 | 2019-05-14 | Optinose As | Delivery device and method |
US9566402B2 (en) | 2003-05-20 | 2017-02-14 | Optinose As | Delivery Device and Method |
US9452272B2 (en) | 2003-08-14 | 2016-09-27 | Optinose As | Delivery devices |
US10737045B2 (en) | 2003-08-28 | 2020-08-11 | Optinose As | Delivery devices |
US8954149B2 (en) | 2004-02-20 | 2015-02-10 | Brainsgate Ltd. | External stimulation of the SPG |
US7908000B2 (en) | 2004-02-20 | 2011-03-15 | Brainsgate Ltd. | Transmucosal electrical stimulation |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US10398859B2 (en) | 2004-09-15 | 2019-09-03 | Optinose As | Nasal delivery devices |
US11571531B2 (en) | 2005-02-23 | 2023-02-07 | OptiNose Inc. | Powder delivery devices |
GB2424587B (en) * | 2005-02-23 | 2010-05-19 | Optinose As | Powder delivery devices |
US8899229B2 (en) | 2005-02-23 | 2014-12-02 | Optinose As | Powder delivery devices |
WO2006100102A1 (fr) * | 2005-03-24 | 2006-09-28 | Iph Establishment | Appareil pour l'administration de produits pharmaceutiques sous forme d'aérosol |
JP2008534036A (ja) * | 2005-03-24 | 2008-08-28 | アイピーエイチ エスタブリッシュメント | エアロゾル形態の薬剤製品を投与するための装置 |
US8958881B2 (en) | 2005-08-19 | 2015-02-17 | Brainsgate Ltd. | Neuroprotective electrical stimulation |
EP1754510A1 (fr) | 2005-08-19 | 2007-02-21 | Brainsgate Ltd. | Stimulation pour le traitement d'événements cérébraux et d'autres conditions |
US10478574B2 (en) | 2006-01-19 | 2019-11-19 | Optinose As | Nasal administration |
US10124132B2 (en) | 2006-03-06 | 2018-11-13 | Optinose As | Nasal delivery |
US10864334B2 (en) | 2006-03-23 | 2020-12-15 | Optinose As | Nasal delivery |
US10112021B2 (en) | 2006-06-08 | 2018-10-30 | Optinose As | Intranasal administration |
US10765829B2 (en) | 2006-07-25 | 2020-09-08 | Optinose As | Delivery of gases to the nasal airway |
US11690969B2 (en) | 2006-07-25 | 2023-07-04 | OptiNose Inc. | Delivery of gases to the nasal airway |
US10639438B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
US20110023869A1 (en) * | 2006-11-28 | 2011-02-03 | Optinose As | Delivery devices |
US10525218B2 (en) | 2006-11-28 | 2020-01-07 | Optinose As | Nasal delivery devices |
US10639437B2 (en) | 2006-11-28 | 2020-05-05 | Optinose As | Delivery devices |
WO2008091588A1 (fr) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Administration intranasale, buccale ou sublinguale d'analogues de métanicotine |
US9649456B2 (en) | 2007-04-05 | 2017-05-16 | Optinose As | Nasal administration |
US10076615B2 (en) | 2007-04-05 | 2018-09-18 | Optinose As | Nasal delivery |
US10722667B2 (en) | 2007-04-05 | 2020-07-28 | Optinose As | Nasal administration |
US11602603B2 (en) | 2007-10-03 | 2023-03-14 | Optinose, Inc. | Nasal delivery devices |
US10252010B2 (en) | 2007-10-03 | 2019-04-09 | Optinose As | Nasal delivery devices |
US11083858B2 (en) | 2007-10-03 | 2021-08-10 | Optinose As | Nasal delivery devices |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
ITBO20090755A1 (it) * | 2009-11-19 | 2011-05-20 | Giorgio Mezzoli | Dispositivo atto a somministrare per via nasale e/o buccale le soluzioni sotto forma di aerosol, doccia micronizzata o nebulizzazione. |
US11291626B2 (en) | 2010-09-14 | 2022-04-05 | Optinose As | Nasal delivery of oxytocin |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
US10179216B2 (en) | 2012-02-24 | 2019-01-15 | Optinose As | Nasal delivery devices |
US10300229B2 (en) | 2012-02-24 | 2019-05-28 | Optinose As | Nasal delivery devices |
US11033696B2 (en) | 2012-02-24 | 2021-06-15 | Optinose As | Nasal delivery devices |
US10076614B2 (en) | 2012-02-24 | 2018-09-18 | Optinose As | Nasal delivery devices |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
USD759805S1 (en) | 2013-05-23 | 2016-06-21 | Optinose As | Nosepiece unit |
USD809128S1 (en) | 2013-05-23 | 2018-01-30 | Optinose As | Nosepiece unit |
USD761951S1 (en) | 2013-05-23 | 2016-07-19 | Optinose As | Nosepiece unit |
USD773644S1 (en) | 2013-05-23 | 2016-12-06 | Optinose As | Nosepiece unit |
US10512771B2 (en) | 2013-11-10 | 2019-12-24 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US11707586B2 (en) | 2014-11-19 | 2023-07-25 | OptiNose Inc. | Intranasal administration |
US11052204B2 (en) | 2014-11-19 | 2021-07-06 | Optinose As | Intranasal administration |
US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
US11730904B2 (en) | 2014-11-19 | 2023-08-22 | Optinose, Inc. | Intranasal administration |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US11524129B2 (en) | 2018-01-23 | 2022-12-13 | Shl Medical Ag | Aerosol generator with obstructed air jets |
JP7101787B2 (ja) | 2018-01-23 | 2022-07-15 | エスエイチエル・メディカル・アーゲー | エアロゾル発生器 |
JP2021509341A (ja) * | 2018-01-23 | 2021-03-25 | エスエイチエル・メディカル・アーゲー | エアロゾル発生器 |
US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
WO2023135237A1 (fr) | 2022-01-14 | 2023-07-20 | Cybin Irl Limited | Compositions de tryptamine et procédés |
WO2023156450A1 (fr) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Compositions de phénéthylamine thérapeutique et procédés d'utilisation |
WO2023156453A1 (fr) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | Dérivés de phénétylamine, compositions et procédés d'utilisation |
WO2023186963A1 (fr) | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Combinaison d'oxyde nitreux et d'agonistes du récepteur 5-ht2a |
Also Published As
Publication number | Publication date |
---|---|
GB0207817D0 (en) | 2002-05-15 |
GB2389315B (en) | 2004-11-24 |
GB2389315A (en) | 2003-12-10 |
AU2003222401A1 (en) | 2003-10-20 |
GB0307820D0 (en) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003084591A1 (fr) | Dispositifs nasaux | |
US7854227B2 (en) | Nasal devices | |
US7347201B2 (en) | Nasal delivery devices | |
US20210290867A1 (en) | Nasal delivery devices | |
EP1988953B1 (fr) | Dispositif d'administration | |
EP1492587B1 (fr) | Dispositifs nasals | |
US10124132B2 (en) | Nasal delivery | |
WO2003020350A1 (fr) | Dispositif d'administration nasale | |
GB2403154A (en) | Nasal inhaler with regulated gas stream | |
GB2402886A (en) | Nasal device with varying pressure gas supply | |
GB2391482A (en) | Nasal delivery devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |